Oreptacog alfa

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameOreptacog alfa
Drug Alias NameFactor VIIa - BayerBAY-86-6150BAY-866150Maxy 968MAXY-VII +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor
Mechanisms of ActionCoagulation factor IX stimulantsCoagulation factor X stimulantsBlood coagulation pathway activation +[4] 
TargetsCoagulation factor IXCoagulation factor X
Therapy Area/IndicationsHemophilia BHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesUkraine +[29] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaPending
Originator CompaniesMaxygen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMaxygenF. Hoffmann-La Roche LtdBayer AG
Active IndicationsN/A
Inactive IndicationsHemophilia BHemophilia A

Other Information

ATC CodeN/A
Related LinksN/A